Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death | Depressive Disorders | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and DeathA Systematic Review and Meta-analysis

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Are preexisting mood disorders associated with higher risk of COVID-19 infection, hospitalization, severe complications, and death?

Findings  In this systematic review and meta-analysis of more than 91 million people, individuals with preexisting mood disorders, compared with those without mood disorders, had significantly higher pooled odds ratios for COVID-19 hospitalization and death. There were no associations between preexisting mood disorders and risk of COVID-19 infection or severe events.

Meaning  These results suggest that individuals with mood disorders should be categorized as an at-risk group for COVID-19 hospitalization and death, providing basis for vaccine prioritization.

Abstract

Importance  Preexisting noncommunicable diseases (eg, diabetes) increase the risk of COVID-19 infection, hospitalization, and death. Mood disorders are associated with impaired immune function and social determinants that increase the risk of COVID-19. Determining whether preexisting mood disorders represent a risk of COVID-19 would inform public health priorities.

Objective  To assess whether preexisting mood disorders are associated with a higher risk of COVID-19 susceptibility, hospitalization, severe complications, and death.

Data Sources  Systematic searches were conducted for studies reporting data on COVID-19 outcomes in populations with and without mood disorders on PubMed/MEDLINE, The Cochrane Library, PsycInfo, Embase, Web of Science, Google/Google Scholar, LitCovid, and select reference lists. The search timeline was from database inception to February 1, 2021.

Study Selection  Primary research articles that reported quantitative COVID-19 outcome data in persons with mood disorders vs persons without mood disorders of any age, sex, and nationality were selected. Of 1950 articles identified through this search strategy, 21 studies were included in the analysis.

Data Extraction and Synthesis  The modified Newcastle-Ottawa Scale was used to assess methodological quality and risk of bias of component studies. Reported adjusted odds ratios (ORs) were pooled with unadjusted ORs calculated from summary data to generate 4 random-effects summary ORs, each corresponding to a primary outcome.

Main Outcomes and Measures  The 4 a priori primary outcomes were COVID-19 susceptibility, COVID-19 hospitalization, COVID-19 severe events, and COVID-19 death. The hypothesis was formulated before study search. Outcome measures between individuals with and without mood disorders were compared.

Results  This review included 21 studies that involved more than 91 million individuals. Significantly higher odds of COVID-19 hospitalization (OR, 1.31; 95% CI, 1.12-1.53; P = .001; n = 26 554 397) and death (OR, 1.51; 95% CI, 1.34-1.69; P < .001; n = 25 808 660) were found in persons with preexisting mood disorders compared with those without mood disorders. There was no association between mood disorders and COVID-19 susceptibility (OR, 1.27; 95% CI, 0.73-2.19; n = 65 514 469) or severe events (OR, 0.94; 95% CI, 0.87-1.03; n = 83 240). Visual inspection of the composite funnel plot for asymmetry indicated the presence of publication bias; however, the Egger regression intercept test result was not statistically significant.

Conclusions and Relevance  The results of this systematic review and meta-analysis examining the association between preexisting mood disorders and COVID-19 outcomes suggest that individuals with preexisting mood disorders are at higher risk of COVID-19 hospitalization and death and should be categorized as an at-risk group on the basis of a preexisting condition.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: May 25, 2021.

Published Online: July 28, 2021. doi:10.1001/jamapsychiatry.2021.1818

Corresponding Author: Roger S. McIntyre, MD, University Health Network, 399 Bathurst St, MP 9-325, Toronto, ON M5T 2S8, Canada (roger.mcintyre@uhn.ca).

Author Contributions: Dr McIntyre had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ceban, Lee, Xiong, Gill, Mansur, Rosenblat, Ho, McIntyre.

Acquisition, analysis, or interpretation of data: Ceban, Nogo, Carvalho, Lee, Nasri, Lui, Subramaniapillai, Liu, Joseph, Teopiz, Cao, Lin, Rosenblat, McIntyre.

Drafting of the manuscript: Ceban, Nogo, Carvalho, Lui, Liu, Teopiz, McIntyre.

Critical revision of the manuscript for important intellectual content: Ceban, Nogo, Carvalho, Lee, Nasri, Xiong, Subramaniapillai, Gill, Joseph, Cao, Mansur, Lin, Rosenblat, Ho, McIntyre.

Statistical analysis: Ceban, Carvalho.

Administrative, technical, or material support: Nogo, Carvalho, Nasri, Xiong, Lui, Subramaniapillai, Gill, Liu, Joseph, Rosenblat.

Supervision: Nogo, Lee, Mansur, Lin, Rosenblat, Ho, McIntyre.

Conflict of Interest Disclosures: Ms Lee reported receiving personal fees from Braxia Scientific Corp outside the submitted work. Ms Lui is a contractor to Braxia Scientific Corp. Ms Teopiz reported receiving personal fees from Braxia Scientific Corp outside the submitted work. Dr Rosenblat is the medical director of Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp), which provides ketamine and esketamine treatment for depression, and has received research grant support from the American Psychiatric Association, American Society of Psychopharmacology, Canadian Cancer Society, Canadian Psychiatric Association, Joseph M. West Family Memorial Fund, Timeposters Fellowship, University Health Network Centre for Mental Health, and University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Dr McIntyre reported receiving grant support from Canadian Institutes of Health Research, Global Alliance for Chronic Diseases, and Chinese National Natural Research Foundation and speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, and AbbVie. Dr McIntyre is a chief executive officer of Braxia Scientific Corp.

References
1.
Keaten  J. WHO: 10% of world’s people may have been infected with virus. Associated Press website. Updated 2020. Accessed February 15, 2020. https://apnews.com/article/virus-outbreak-archive-united-nations-54a3a5869c9ae4ee623497691e796083
2.
Wiersinga  WJ , Rhodes  A , Cheng  AC , Peacock  SJ , Prescott  HC . Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782-793. doi:10.1001/jama.2020.12839
3.
Jordan  RE , Adab  P , Cheng  KK . Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. doi:10.1136/bmj.m1198
4.
Huang  Y , Lu  Y , Huang  YM ,  et al.  Obesity in patients with COVID-19: a systematic review and meta-analysis.   Metabolism. 2020;113:154378. doi:10.1016/j.metabol.2020.154378 PubMedGoogle Scholar
5.
Xiong  J , Lipsitz  O , Nasri  F ,  et al.  Impact of COVID-19 pandemic on mental health in the general population: a systematic review.   J Affect Disord. 2020;277:55-64. doi:10.1016/j.jad.2020.08.001 PubMedGoogle ScholarCrossref
6.
Rosenblat  JD , Cha  DS , Mansur  RB , McIntyre  RS . Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:23-34. doi:10.1016/j.pnpbp.2014.01.013
7.
Rosenblat  JD , McIntyre  RS .  Bipolar disorder and inflammation.   Psychiatr Clin North Am. 2016;39(1):125-137. doi:10.1016/j.psc.2015.09.006 PubMedGoogle ScholarCrossref
8.
Fenton  WS , Stover  ES .  Mood disorders: cardiovascular and diabetes comorbidity.   Curr Opin Psychiatry. 2006;19(4):421-427. doi:10.1097/01.yco.0000228765.33356.9f PubMedGoogle ScholarCrossref
9.
McIntyre  RS , Carvalho  AF .  Mood disorders and general medical comorbidities: shared biology and novel therapeutic targets.   Curr Mol Med. 2016;16(2):104-105. doi:10.2174/1566524016999160127110934 PubMedGoogle ScholarCrossref
10.
Varatharaj  A , Thomas  N , Ellul  MA ,  et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875-882. doi:10.1016/S2215-0366(20)30287-X
11.
Mukaetova-Ladinska  E , Kronenberg  G .  Psychological and neuropsychiatric implications of COVID-19.   Eur Arch Psychiatry Clin Neurosci. 2021;271(2):235-248. doi:10.1007/s00406-020-01210-2PubMedGoogle ScholarCrossref
12.
Taquet  M , Geddes  JR , Husain  M , Luciano  S , Harrison  PJ . 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5
13.
Yao  H , Chen  JH , Xu  YF .  Patients with mental health disorders in the COVID-19 epidemic.   Lancet Psychiatry. 2020;7(4):e21. doi:10.1016/S2215-0366(20)30090-0 PubMedGoogle Scholar
14.
Shinn  AK , Viron  M .  Perspectives on the COVID-19 pandemic and individuals with serious mental illness.   J Clin Psychiatry. 2020;81(3):20. doi:10.4088/JCP.20com13412 PubMedGoogle ScholarCrossref
15.
Mazereel  V , Van Assche  K , Detraux  J , De Hert  M. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021;8(5):444-450. doi:10.1016/S2215-0366(20)30564-2
16.
Toubasi  AA , AbuAnzeh  RB , Tawileh  HBA , Aldebei  RH , Alryalat  SAS .  A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders.   Psychiatry Res. 2021;299:113856. doi:10.1016/j.psychres.2021.113856 PubMedGoogle Scholar
17.
Steel  Z , Marnane  C , Iranpour  C ,  et al.  The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013.   Int J Epidemiol. 2014;43(2):476-493. doi:10.1093/ije/dyu038 PubMedGoogle ScholarCrossref
18.
Stroup  DF , Berlin  JA , Morton  SC ,  et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008
19.
Moher  D , Liberati  A , Tetzlaff  J , Altman  DG ; PRISMA Group.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.   BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535 PubMedGoogle ScholarCrossref
20.
Stang  A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605. doi:10.1007/s10654-010-9491-z
21.
Higgins  JPT , Li  T , Deeks  JJ .  Choosing effect measures and computing estimates of effect. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2019:143-176. doi:10.1002/9781119536604.ch6
22.
Chang  TS , Ding  Y , Freund  MK ,  et al.  Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System.  Preprint posted online July 4, 2020. medRxiv. doi:10.1101/2020.07.03.20145581
23.
Chang M, Moonesinghe R, Truman BI. COVID-19 hospitalization by race and ethnicity: association with chronic conditions among Medicare beneficiaries, January 1-September 30, 2020. J Racial Ethn Health Disparities. 2021:1-10. doi:10.1007/s40615-020-00960-y
24.
Haimovich  AD , Warner  F , Young  HP ,  et al. Patient factors associated with SARS-CoV-2 in an admitted emergency department population. Ann Emerg Med. 2020;1(4):569-577. doi:10.1002/emp2.12145
25.
Izurieta  HS , Graham  DJ , Jiao  Y ,  et al. Natural history of coronavirus disease 2019: risk factors for hospitalizations and deaths among >26 million US Medicare beneficiaries. J Infect Dis. 2021;223(6):945-956. doi:10.1093/infdis/jiaa767
26.
Jeon  HL , Kwon  JS , Park  SH , Shin  JY .  Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study.   Br J Psychiatry. 2021:1-8. doi:10.1192/bjp.2020.251PubMedGoogle Scholar
27.
Ji  W , Huh  K , Kang  M ,  et al.  Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study.   J Korean Med Sci. 2020;35(25):e237. doi:10.3346/jkms.2020.35.e237 PubMedGoogle Scholar
28.
Orlando  V , Rea  F , Savaré  L ,  et al.  Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy.   PLoS One. 2021;16(1):e0237202. doi:10.1371/journal.pone.0237202 PubMedGoogle Scholar
29.
Poblador-Plou  B , Carmona-Pírez  J , Ioakeim-Skoufa  I ,  et al; EpiChron Group.  Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: results from the PRECOVID study in Spain.   Int J Environ Res Public Health. 2020;17(14):5171. doi:10.3390/ijerph17145171 PubMedGoogle ScholarCrossref
30.
Rodríguez-Molinero  A , Gálvez-Barrón  C , Miñarro  A ,  et al; COVID-19 Research Group of CSAPG.  Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients.   PLoS One. 2020;15(10):e0239571. doi:10.1371/journal.pone.0239571 PubMedGoogle Scholar
31.
Tang  O , Bigelow  BF , Sheikh  F ,  et al.  Outcomes of nursing home COVID-19 patients by initial symptoms and comorbidity: results of universal testing of 1970 residents.   J Am Med Dir Assoc. 2020;21(12):1767-1773.e1. doi:10.1016/j.jamda.2020.10.011 PubMedGoogle ScholarCrossref
32.
Yang  H , Chen  W , Hu  Y ,  et al. Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank cohort analysis. Lancet Healthy Longev. 2020;1(2):e69-e79. doi:10.1016/S2666-7568(20)30013-1
33.
Murk  W , Gierada  M , Fralick  M , Weckstein  A , Klesh  R , Rassen  JA .  Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study.   CMAJ. 2021;193(1):E10-E18. doi:10.1503/cmaj.201686 PubMedGoogle ScholarCrossref
34.
Taquet  M , Luciano  S , Geddes  JR , Harrison  PJ . Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130-140. doi:10.1016/S2215-0366(20)30462-4
35.
van der Meer  D , Pinzón-Espinosa  J , Lin  BD ,  et al.  Associations between psychiatric disorders, COVID-19 testing probability and COVID-19 testing results: findings from a population-based study.   B J Psych Open. 2020;6(5):e87. doi:10.1192/bjo.2020.75 PubMedGoogle Scholar
36.
Yanover  C , Mizrahi  B , Kalkstein  N ,  et al.  What factors increase the risk of complications in SARS-CoV-2-infected patients? a cohort study in a nationwide Israeli health organization.   JMIR Public Health Surveill. 2020;6(3):e20872. doi:10.2196/20872 PubMedGoogle Scholar
37.
Kundi  H , Çetin  EHÖ , Canpolat  U ,  et al. The role of frailty on adverse outcomes among older patients with COVID-19. J Infect. 2020;81(6):944-951. doi:10.1016/j.jinf.2020.09.029
38.
Douville  NJ , Douville  CB , Mentz  G ,  et al. Clinically applicable approach for predicting mechanical ventilation in patients with COVID-19. Br J Anaesth. 2021;126(3):578-589. doi:10.1016/j.bja.2020.11.034
39.
Azar  K , Shen  Z , Romanelli  RJ ,  et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff (Millwood). 2020;39(7):1253-1262. doi:10.1377/hlthaff.2020.00598
40.
Nemani  K , Li  C , Olfson  M ,  et al.  Association of psychiatric disorders with mortality among patients with COVID-19.   JAMA Psychiatry. 2021;78(4):380-386. doi:10.1001/jamapsychiatry.2020.4442 PubMedGoogle ScholarCrossref
41.
Wang  Q , Xu  R , Volkow  ND . Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124-130. doi:10.1002/wps.20806
42.
Salvatore  M , Gu  T , Mack  JA ,  et al.  A phenome-wide association study (PheWAS) of COVID-19 outcomes by race using the electronic health records data in Michigan Medicine.  J Clin Med. 2021;10(7):1351. doi:10.3390/jcm10071351
43.
Barili  F , Parolari  A , Kappetein  PA , Freemantle  N . Statistical Primer: heterogeneity, random- or fixed-effects model analyses? Interact CardioVasc Thorac Surg. 2018;27(3):317-321. doi:10.1093/icvts/ivy163
44.
Deeks JJ, Higgins JPT, Altman DG, eds. Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2008:243-296. doi:10.1002/9780470712184.ch9
45.
Schünemann H.J., Higgins JPT, Vist GE, et al, eds.  Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2019:375-402. doi:10.1002/9781119536604.ch14
46.
Paakkari  L , Okan  O . COVID-19: health literacy is an underestimated problem. Lancet Public Health. 2020;5(5):e249-e250. doi:10.1016/S2468-2667(20)30086-4
47.
Abrams  EM , Szefler  SJ . COVID-19 and the impact of social determinants of health. Lancet Respir Med. 2020;8(7):659-661. doi:10.1016/S2213-2600(20)30234-4
48.
Zhu  Y , Chen  L , Ji  H , Xi  M , Fang  Y , Li  Y .  The risk and prevention of novel coronavirus pneumonia infections among inpatients in psychiatric hospitals.   Neurosci Bull. 2020;36(3):299-302. doi:10.1007/s12264-020-00476-9 PubMedGoogle ScholarCrossref
49.
Kar  SK , Arafat  SMY , Marthoenis  M , Kabir  R .  Homeless mentally ill people and COVID-19 pandemic: the two-way sword for LMICs.   Asian J Psychiatr. 2020;51:102067. doi:10.1016/j.ajp.2020.102067 PubMedGoogle Scholar
50.
Dickerson  F , Schroeder  J , Katsafanas  E ,  et al. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv. 2018;69(2):147-153. doi:10.1176/appi.ps.201700118
51.
Covey  LS , Glassman  AH , Stetner  F . Cigarette smoking and major depression. J Addict Dis. 1998;17(1):35-46. doi:10.1300/J069v17n01_04
52.
Wang  QQ , Kaelber  DC , Xu  R , Volkow  ND . COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30-39. doi:10.1038/s41380-020-00880-7
53.
Hert MDE, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77. doi:10.1002/j.2051-5545.2011.tb00014.x
54.
Brietzke  E , Stertz  L , Fernandes  BS ,  et al.  Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder.   J Affect Disord. 2009;116(3):214-217. doi:10.1016/j.jad.2008.12.001 PubMedGoogle ScholarCrossref
55.
Miller  AH .  Depression and immunity: a role for T cells?   Brain Behav Immun. 2010;24(1):1-8. doi:10.1016/j.bbi.2009.09.009 PubMedGoogle ScholarCrossref
56.
Howren  MB , Lamkin  DM , Suls  J .  Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.   Psychosom Med. 2009;71(2):171-186. doi:10.1097/PSY.0b013e3181907c1b PubMedGoogle ScholarCrossref
57.
Dowlati  Y , Herrmann  N , Swardfager  W ,  et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457. doi:10.1016/j.biopsych.2009.09.033
58.
Giamarellos-Bourboulis  E , Netea  MG , Rovina  N ,  et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3. doi:10.1016/j.chom.2020.04.009
59.
Obiora  E , Hubbard  R , Sanders  RD , Myles  PR .  The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort.   Thorax. 2013;68(2):163-170. doi:10.1136/thoraxjnl-2012-202374 PubMedGoogle ScholarCrossref
60.
Dzahini  O , Singh  N , Taylor  D , Haddad  PM . Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol. 2018;32(11):1167-1181. doi:10.1177/0269881118795333
61.
de Leon  J , Ruan  CJ , Verdoux  H , Wang  C .  Clozapine is strongly associated with the risk of pneumonia and inflammation.   Gen Psychiatr. 2020;33(2):e100183. doi:10.1136/gpsych-2019-100183 PubMedGoogle Scholar
62.
Govind  R , Fonseca de Freitas  D , Pritchard  M , Hayes  RD , MacCabe  JH .  Clozapine treatment and risk of COVID-19 infection: retrospective cohort study.   Br J Psychiatry. 2020:1-7. doi:10.1192/bjp.2020.151 PubMedGoogle Scholar
63.
Raison  CL , Pikalov  A , Siu  C , Tsai  J , Koblan  K , Loebel  A .  C-reactive protein and response to lurasidone in patients with bipolar depression.   Brain Behav Immun. 2018;73:717-724. doi:10.1016/j.bbi.2018.08.009 PubMedGoogle ScholarCrossref
64.
Beurel  E , Jope  RS . Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry. 2014;4(12):e488. doi:10.1038/tp.2014.129
65.
Landén  M , Larsson  H , Lichtenstein  P , Westin  J , Song  J . Respiratory infections during lithium and valproate medication: a within-individual prospective study of 50,000 patients with bipolar disorder. Int J Bipolar Disord. 2021;9(1):4. doi:10.1186/s40345-020-00208-y
66.
Nobile  B , Durand  M , Olié  E ,  et al. Clomipramine could be useful in preventing neurological complications of SARS-CoV-2 infection. J Neuroimmune Pharmacol. 2020;15(3):347-348. doi:10.1007/s11481-020-09939-2
67.
Hoertel  N , Sánchez-Rico  M , Vernet  R ,  et al; AP-HP / Universities/INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative.  Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study.   Mol Psychiatry. 2021. doi:10.1038/s41380-021-01021-4 PubMedGoogle Scholar
68.
Zimering  MB , Razzaki  T , Tsang  T , Shin  JJ .  Inverse association between serotonin 2A receptor antagonist medication use and mortality in severe COVID-19 infection.   Endocrinol Diabetes Metab J. 2020;4(4):1-5. https://pubmed.ncbi.nlm.nih.gov/33117497.PubMedGoogle Scholar
69.
Seftel  D , Boulware  DR . Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2):ofab050. doi:10.1093/ofid/ofab050
70.
Lenze  EJ , Mattar  C , Zorumski  CF ,  et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292-2300. doi:10.1001/jama.2020.22760
71.
Lu  Y , Ho  CS , Liu  X ,  et al.  Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression.   PLoS One. 2017;12(10):e0186700. doi:10.1371/journal.pone.0186700 PubMedGoogle Scholar
72.
Zimniak  M , Kirschner  L , Hilpert  H , Seibel  J , Bodem  J .  The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2.  Published online June 17, 2020. bioRxiv 5809.
73.
Rosenthal  N , Cao  Z , Gundrum  J , Sianis  J , Safo  S . Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020;3(12):e2029058. doi:10.1001/jamanetworkopen.2020.29058
74.
Li  M , Cheng  B , Zeng  W ,  et al.  Analysis of the risk factors for mortality in adult COVID-19 patients in Wuhan: a multicenter study.   Front Med (Lausanne). 2020;7:545. doi:10.3389/fmed.2020.00545 PubMedGoogle ScholarCrossref
75.
Kim  W , Han  JM , Lee  KE . Predictors of mortality in patients with COVID-19: a systematic review and meta-analysis. Korean J Clin Pharmacy. 2020;30(3):169-176. doi:10.24304/kjcp.2020.30.3.169
76.
Zhang  F , Xiong  Y , Wei  Y ,  et al. Obesity predisposes to the risk of higher mortality in young COVID-19 patients. J Med Virol. 2020;92(11):2536-2542. doi:10.1002/jmv.26039
77.
McIntyre  RS , Berk  M , Brietzke  E ,  et al. Bipolar disorders. Lancet. 2020;396(10265):1841-1856. doi:10.1016/S0140-6736(20)31544-0
78.
Yoo  JY , Dutra  SVO , Fanfan  D ,  et al. Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti. BMC Public Health. 2020;20(1):1853. doi:10.1186/s12889-020-09924-7
79.
Page  MJ , Higgins  JPT , Sterne  JAC . Assessing risk of bias due to missing results in a synthesis. In: Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2019:349-374.
80.
Liao  YH , Fan  BF , Zhang  HM ,  et al.  The impact of COVID-19 on subthreshold depressive symptoms: a longitudinal study.   Epidemiol Psychiatr Sci. 2021;30:e20. doi:10.1017/S2045796021000044 PubMedGoogle Scholar
81.
Wang  C , Pan  R , Wan  X ,  et al.  A longitudinal study on the mental health of general population during the COVID-19 epidemic in China.   Brain Behav Immun. 2020;87:40-48. doi:10.1016/j.bbi.2020.04.028 PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close